IN-VITRO GLUCOCORTICOID STUDIES FOR PREDICTING RESPONSE TO GLUCOCORTICOID THERAPY IN ADULTS WITH MALIGNANT LYMPHOMA

Clara D. Bloomfield; Bruce A. Peterson; Joann Zaleskas; Glauco Frizzera; Kendall A. Smith; Laurie Hildebrandt; Kazimiera J. Gajl-Peczalska; Allan Munck

doi:10.1016/S0140-6736(80)91405-1

IN-VITRO GLUCOCORTICOID STUDIES FOR PREDICTING RESPONSE TO GLUCOCORTICOID THERAPY IN ADULTS WITH MALIGNANT LYMPHOMA

Clara D. Bloomfield, Bruce A. Peterson, Joann Zaleskas, Glauco Frizzera, Kendall A. Smith, Laurie Hildebrandt, Kazimiera J. Gajl-Peczalska, Allan Munck

Medicine - Hematology, Oncology, Transplant

Research output: Contribution to journal › Article › peer-review

44 Scopus citations

Abstract

Neoplastic tissues from 28 adults with malignant lymphoma were examined for glucocorticoid receptors and in-vitro sensitivity to glucocorticoids. The patients were then treated with dexamethasone for 5-14 days. 13 patients achieved at least a partial remission, and 15 had no significant tumour response. Lymphoma cells from patients who responded had more glucocorticoid-receptor sites per cell and greater in-vitro sensitivity as measured by glucocorticoid inhibition of incorporation of leucine and uridine than did tumour cells from non-responders. Study of tumour glucocorticoid receptors and glucocorticoid sensitivity in vitro may allow selection of those patients with lymphoma who should receive glucocorticoids as part of combination chemotherapy.

Original language	English (US)
Pages (from-to)	952-956
Number of pages	5
Journal	The Lancet
Volume	315
Issue number	8175
DOIs	https://doi.org/10.1016/S0140-6736(80)91405-1
State	Published - May 3 1980

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1016/S0140-6736(80)91405-1

OpenUrl availability

Full text

Cite this

@article{8e8bea3268364c9289e1e53079388a89,

title = "IN-VITRO GLUCOCORTICOID STUDIES FOR PREDICTING RESPONSE TO GLUCOCORTICOID THERAPY IN ADULTS WITH MALIGNANT LYMPHOMA",

abstract = "Neoplastic tissues from 28 adults with malignant lymphoma were examined for glucocorticoid receptors and in-vitro sensitivity to glucocorticoids. The patients were then treated with dexamethasone for 5-14 days. 13 patients achieved at least a partial remission, and 15 had no significant tumour response. Lymphoma cells from patients who responded had more glucocorticoid-receptor sites per cell and greater in-vitro sensitivity as measured by glucocorticoid inhibition of incorporation of leucine and uridine than did tumour cells from non-responders. Study of tumour glucocorticoid receptors and glucocorticoid sensitivity in vitro may allow selection of those patients with lymphoma who should receive glucocorticoids as part of combination chemotherapy.",

author = "Bloomfield, {Clara D.} and Peterson, {Bruce A.} and Joann Zaleskas and Glauco Frizzera and Smith, {Kendall A.} and Laurie Hildebrandt and Gajl-Peczalska, {Kazimiera J.} and Allan Munck",

year = "1980",

month = may,

day = "3",

doi = "10.1016/S0140-6736(80)91405-1",

language = "English (US)",

volume = "315",

pages = "952--956",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier Limited",

number = "8175",

}

TY - JOUR

T1 - IN-VITRO GLUCOCORTICOID STUDIES FOR PREDICTING RESPONSE TO GLUCOCORTICOID THERAPY IN ADULTS WITH MALIGNANT LYMPHOMA

AU - Bloomfield, Clara D.

AU - Peterson, Bruce A.

AU - Zaleskas, Joann

AU - Frizzera, Glauco

AU - Smith, Kendall A.

AU - Hildebrandt, Laurie

AU - Gajl-Peczalska, Kazimiera J.

AU - Munck, Allan

PY - 1980/5/3

Y1 - 1980/5/3

N2 - Neoplastic tissues from 28 adults with malignant lymphoma were examined for glucocorticoid receptors and in-vitro sensitivity to glucocorticoids. The patients were then treated with dexamethasone for 5-14 days. 13 patients achieved at least a partial remission, and 15 had no significant tumour response. Lymphoma cells from patients who responded had more glucocorticoid-receptor sites per cell and greater in-vitro sensitivity as measured by glucocorticoid inhibition of incorporation of leucine and uridine than did tumour cells from non-responders. Study of tumour glucocorticoid receptors and glucocorticoid sensitivity in vitro may allow selection of those patients with lymphoma who should receive glucocorticoids as part of combination chemotherapy.

AB - Neoplastic tissues from 28 adults with malignant lymphoma were examined for glucocorticoid receptors and in-vitro sensitivity to glucocorticoids. The patients were then treated with dexamethasone for 5-14 days. 13 patients achieved at least a partial remission, and 15 had no significant tumour response. Lymphoma cells from patients who responded had more glucocorticoid-receptor sites per cell and greater in-vitro sensitivity as measured by glucocorticoid inhibition of incorporation of leucine and uridine than did tumour cells from non-responders. Study of tumour glucocorticoid receptors and glucocorticoid sensitivity in vitro may allow selection of those patients with lymphoma who should receive glucocorticoids as part of combination chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0018864569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018864569&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(80)91405-1

DO - 10.1016/S0140-6736(80)91405-1

M3 - Article

C2 - 6103302

AN - SCOPUS:0018864569

SN - 0140-6736

VL - 315

SP - 952

EP - 956

JO - The Lancet

JF - The Lancet

IS - 8175

ER -

IN-VITRO GLUCOCORTICOID STUDIES FOR PREDICTING RESPONSE TO GLUCOCORTICOID THERAPY IN ADULTS WITH MALIGNANT LYMPHOMA

Abstract

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this